bluebird bio Reports Third Quarter 2016 Financial Results And Recent Operational Progress

Published: Nov 02, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today reported business highlights and financial results for the third quarter ended September 30, 2016.

Back to news